Completed PHASE2 INTERVENTIONAL 3-arm NCT02108262

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.

Sponsor: CSL Behring

Conditions Acute Myocardial Infarction

Interventions CSL112 Placebo

Updated 8 times since 2017 Last updated: Feb 19, 2021 Started: Aug 31, 2014 Primary completion: Dec 31, 2015 Completion: Mar 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Myocardial Infarction and is currently completed. CSL Behring leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSL Behring

Data source: CSL Behring

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aalborg, Denmark , Adelaide, Australia , Alexandria, United States , Alkmaar, Netherlands , Amarillo, United States , Amsterdam, Netherlands , Ashkelon, Israel , Atlanta, United States , Auburn, United States and 151 more locations